Business
OBD Prostate Screening EpiSwitch Blood Test Update
OBD Prostate Screening EpiSwitch Blood Test Update.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n Oxford Biodynamics' Prostate Screening EpiSwitch® blood test significantly enhances overall detection accuracy for at risk men\n \n \n \n \n \n \n \n \n · \n \n Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic\n \n \n \n ·\n \n High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact, peer-reviewed journal Cancers\n \n \n \n · \n \n Experts from Oxford Biodynamics, Imperial College London,\n \n \n University of East Anglia,\n \n \n and Imperial College NHS Trust\n \n \n contributed to multi-institutional clinical study\n \n \n \n · \n \n This published data packet supports commercialization of the EpiSwitch® platform which includes this novel and accurate prostate cancer test\n \n \n \n \n \n \n \n Oxford, UK - 6 February, 2023\n \n -\n Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD's technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent\n \n results statement.\n \n \n \n \n \n \n The peer-reviewed work, published in the high-impact journal,\n Cancers\n , was a collaboration between OBD, Imperial College London,\n \n University of East Anglia,\n and Imperial College National Health Service (NHS) Trust under the direction of the UK's leading prostate cancer experts.\n \n \n \n \n \n The NHS considers the widely available prostate-specific antigen (PSA) test as inaccurate1. A positive result from a standard PSA test is unreliable and often suggests prostate cancer is present when no cancer exists. The inaccuracy of current screening protocols leads to many men getting unnecessary referrals for expensive MRI scans and highly invasive, medieval biopsies.\n Only about a quarter of people who have a prostate biopsy due to an elevated PSA level are found to have prostate cancer2.\n \n \n \n \n \n \n In the PROSTAGRAM screening pilot study, blood from 147 men enrolled in the study and patients from Imperial College NHS Trust were tested using the standard prostate-specific antigen (PSA) test and an E...